1.505
Neuronetics Inc stock is traded at $1.505, with a volume of 2.09M.
It is down -9.06% in the last 24 hours and up +11.48% over the past month.
Neuronetics Inc a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advance Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advance Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address the existing treatment options. The company operates in two segments: medical devices and clinic services.
See More
Previous Close:
$1.655
Open:
$1.66
24h Volume:
2.09M
Relative Volume:
0.90
Market Cap:
$104.73M
Revenue:
$151.64M
Net Income/Loss:
$-37.23M
P/E Ratio:
-3.8452
EPS:
-0.3914
Net Cash Flow:
$-21.18M
1W Performance:
-25.50%
1M Performance:
+11.48%
6M Performance:
-31.59%
1Y Performance:
-66.03%
Neuronetics Inc Stock (STIM) Company Profile
Name
Neuronetics Inc
Sector
Industry
Phone
877-600-7555
Address
3222 PHOENIXVILLE PIKE, MALVERN, PA
Compare STIM vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
STIM
Neuronetics Inc
|
1.505 | 115.17M | 151.64M | -37.23M | -21.18M | -0.3914 |
|
ABT
Abbott Laboratories
|
82.56 | 146.87B | 45.13B | 6.28B | 7.38B | 3.5895 |
|
SYK
Stryker Corp
|
282.58 | 109.33B | 25.27B | 3.34B | 4.57B | 8.6358 |
|
MDT
Medtronic Plc
|
74.54 | 97.77B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
53.37 | 80.16B | 20.62B | 3.56B | 3.48B | 2.3847 |
|
EW
Edwards Lifesciences Corp
|
77.17 | 46.04B | 6.30B | 1.07B | 1.09B | 1.8406 |
Neuronetics Inc Stock (STIM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-13-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-13-21 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-13-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jan-22-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Feb-06-20 | Initiated | BTIG Research | Buy |
| Jul-24-18 | Initiated | Canaccord Genuity | Buy |
View All
Neuronetics Inc Stock (STIM) Latest News
MSN Money - MSN
Neuronetics (STIM) Q1 2026 Earnings Transcript - AOL.com
Neuronetics outlines $160M-$166M 2026 revenue outlook with focus on $2.5M-$3M annualized cost savings - MSN
Full Transcript: Neuronetics Q1 2026 Earnings Call - Sahm
Neuronetics, Inc. (NASDAQ:STIM) Q1 2026 Earnings Call Transcript - Insider Monkey
Neuronetics Q1 2026 slides: revenue rises 8% amid profitability push By Investing.com - Investing.com Australia
Geopolitical Turmoil and Supply Chain Strains Threaten Neuronetics’ Costs, Margins, and Growth - TipRanks
Neuronetics Q1 Earnings Call Highlights - Yahoo Finance
Neuronetics, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Neuronetics STIM Stock Jumps As Activist Pressure Meets Growth Tailwinds - StocksToTrade
Neuronetics Grants Inducement Awards to Six New Employees - MyChesCo
Neuronetics Q1 2026 slides: revenue rises 8% amid profitability push - Investing.com
Neuronetics, Inc. 1Q 2026: Revenue $34.45M, EPS ($0.16) — 10-Q Summary - TradingView
Earnings call transcript: Neuronetics Q1 2026 shows revenue growth despite EPS miss - Investing.com
Neuronetics (STIM) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Debt covenants and going concern warning weigh on Neuronetics (NASDAQ: STIM) - Stock Titan
Neuronetics Posts Q1 Revenue Growth and Expanded TMS Coverage - TipRanks
Neuronetics : STIM Corporate Presentation May 2026 - marketscreener.com
Q1 2026 Neuronetics Inc Earnings Call Transcript - GuruFocus
Neuronetics Inc (NASDAQ:STIM) Posts Narrower Loss in Q1 2026, Pre-Market Rises Despite Revenue Miss - ChartMill
Neuronetics Reports First Quarter 2026 Financial and Operating Results - The Manila Times
NEURONETICS ($STIM) Releases Q1 2026 Earnings - Quiver Quantitative
Neuronetics (NASDAQ: STIM) posts 8% Q1 2026 revenue growth and updates 2026 outlook - Stock Titan
Neuronetics: Q1 Earnings Snapshot - KVUE
Optum policy change opens NeuroStar TMS to 34.8M covered lives - Stock Titan
BRIEF-Neuronetics Q1 Gross Margin 46.9% - TradingView
Neuronetics, Inc. Provides Earnings Guidance for the Second Quarter and Full Year 2026 - marketscreener.com
Neuronetics (STIM) Margin Compression Reinforces Bearish Clinic Mix Narrative - Sahm
How The Neuronetics (STIM) Investment Story Is Evolving With A Reset Price Target - Yahoo Finance
Neuronetics Inc expected to post a loss of 17 cents a shareEarnings Preview - TradingView
Short Interest in Neuronetics, Inc. (NASDAQ:STIM) Rises By 16.4% - MarketBeat
STIM SEC FilingsNeuronetics 10-K, 10-Q, 8-K Forms - Stock Titan
Earnings Preview: Neuronetics to Report Financial Results Pre-market on May 05 - Moomoo
Neuronetics CFO Steven Pfanstiel to depart; company begins search for successor - MSN
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Primer: Neuronetics Inc (STIM US)Apr 2026 - Smartkarma
New Neuronetics hires get stock awards that vest over up to 4 years - Stock Titan
Why is STIM stock rallying 16% after-hours? - MSN
Neuronetics (STIM) Projected to Post Earnings on Tuesday - MarketBeat
STIMNeuronetics Inc Stock Price and Quote - Finviz
Neuronetics Schedules Q1 2026 Earnings Release and Call - MyChesCo
Neuronetics (STIM) price target increased by 44.44% to 4.42 - MSN
Neuronetics targets $40M–$43M Q4 revenue as SPRAVATO mix drives full-year outlook - MSN
Neuronetics Inc Stock (STIM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):